Clinical risk scoring models for prediction of acute kidney injury after living donor liver transplantation: A retrospective observational study

PLoS ONE

Volumn 10, Issue 8, 2015, Pages

  Park, Mi Hye ^a   Shim, Haeng Seon ^b   Kim, Won Ho ^b   Kim, Hyo Jin ^b   Kim, Dong Joon ^b   Lee, Seong Ho ^b   Kim, Chung Su ^a   Gwak, Mi Sook ^a   Kim, Gaab Soo ^a  

^a Samsung Medical Center   (South Korea)

^b School of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CYCLOSPORIN; GLUCOSE; MYCOPHENOLATE MOFETIL; SERUM ALBUMIN; TACROLIMUS; GLUCOSE BLOOD LEVEL;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLEEDING; BODY MASS; CRYOPRECIPITATE; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INCIDENCE; ISCHEMIA; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LIVING DONOR LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MODEL FOR END STAGE LIVER DISEASE SCORE; OBSERVATIONAL STUDY; OPERATION DURATION; POSTREPERFUSION SYNDROME; PREDICTION; RENAL REPLACEMENT THERAPY; REPERFUSION INJURY; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SCORING SYSTEM; STATISTICAL ANALYSIS; STATISTICAL MODEL; ACUTE KIDNEY INJURY; ADVERSE EFFECTS; BLOOD TRANSFUSION; HOSPITAL MORTALITY; HYPERGLYCEMIA; LIVER DISEASE; LIVING DONOR; MULTIVARIATE ANALYSIS; PATHOPHYSIOLOGY;

ACUTE KIDNEY INJURY; ADULT; BLOOD GLUCOSE; BLOOD TRANSFUSION; FEMALE; HOSPITAL MORTALITY; HUMANS; HYPERGLYCEMIA; LIVER DISEASES; LIVER TRANSPLANTATION; LIVING DONORS; MULTIVARIATE ANALYSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS;

EID: 84942883113     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0136230     Document Type: Article

References (62)

1. Utsumi M, Umeda Y, Sadamori H, Nagasaka T, Takaki A, Matsuda H, et al. Risk factors for acute renal injury in living donor liver transplantation: evaluation of the RIFLE criteria. Transpl Int. 2013;26:842-852. doi: 10.1111/tri.12138 PMID: 23855657
2. Zhu M, Li Y, Xia Q, Wang S, Qiu Y, Che M, et al. Strong impact of acute kidney injury on survival after liver transplantation. Transplant Proc. 2010;42:3634-3638. doi: 10.1016/j.transproceed.2010.08.059 PMID: 21094830
3. Lebron Gallardo M, Herrera Gutierrez ME, Seller Perez G, Curiel Balsera E, Fernandez Ortega JF, Quesada Garcia G. Riskfactors for renal dysfunction in the postoperative course of liver transplant. LiverTranspl. 2004;10:1379-1385. PMID: 15497160
4. Borthwick E, Ferguson A. Perioperative acute kidney injury: riskfactors, recognition, management, and outcomes. BMJ. 2010;341:c3365. doi: 10.1136/bmj.c3365 PMID: 20603317
5. Barri YM, Sanchez EQ, Jennings LW, Melton LB, Hays S, Levy MF, et al. Acute kidney injury following liver transplantation: definition and outcome. LiverTranspl. 2009;15:475-483. doi: 10.1002/lt.21682 PMID: 19399734
6. Thomas ME, Blaine C, Dawnay A, Devonald MA, Ftouh S, Laing C, et al. The definition of acute kidney injury and its use in practice. Kidney Int. 2015;87:62-73. doi: 10.1038/ki.2014.328 PMID: 25317932
7. Umbro I, Tinti F, Mordenti M, Rossi M, Ianni S, Pugliese F, et al. Model for end-stage liver disease score versus simplified acute physiology score criteria in acute renal failure after liver transplantation. Transplant Proc. 2011;43:1139-1141. doi: 10.1016/j.transproceed.2011.02.045 PMID: 21620072
8. Lee SK, Park JB, Kim SJ, Choi GS, Kim DJ, Kwon CH, et al. Early postoperative renal dysfunction in the adult living donorlivertransplantation. Transplant Proc. 2007;39:1517-1519. PMID: 17580177
9. Kim SG, Kim HJ, Lee JP, Lee SG, Kim YS, Ahn C, et al. Incidence and riskfactors of renal dysfunction after liver transplantation in Korea. Transplant Proc. 2004;36:2318-2320. PMID: 15561236
10. Ferreira AC, Nolasco F, Carvalho D, Sampaio S, Baptista A, Pessegueiro P, et al. Impact of RIFLE classification in livertransplantation. Clin Transplant. 2010;24:394-400. doi: 10.1111/j.1399-0012.2009. 01087.x PMID: 19744093
11. O'Riordan A, Wong V, McQuillan R, McCormick PA, Hegarty JE, Watson AJ. Acute renal disease, as defined by the RIFLE criteria, post-liver transplantation. Am J Transplant. 2007;7:168-176. PMID: 17109735
12. Kundakci A, Pirat A, Komurcu O, Torgay A, Karakayali H, Arslan G, et al. Rifle criteria for acute kidney dysfunction following livertransplantation: incidence and riskfactors. Transplant Proc. 2010;42:4171-4174. doi: 10.1016/j.transproceed.2010.09.137 PMID: 21168655
13. Akamatsu N, Sugawara Y, Tamura S, Kakeno J, Togashi J, Makuuchi M. Renal impairment after living donor livertransplantation. Transplant Proc. 2006;38:1474-1476. PMID: 16797337
14. Inoue Y, Soyama A, Takatsuki M, Hidaka M, Muraoka I, Kanematsu T, et al. Acute kidney injury following living donor livertransplantation. Clin Transplant. 2012;26:E530-535. doi: 10.1111/ctr.12027 PMID: 23061762
15. Chen J, Singhapricha T, Hu KQ, Hong JC, Steadman RH, Busuttil RW, et al. Postliver transplant acute renal injury and failure by the RIFLE criteria in patients with normal pretransplant serum creatinine concentrations: a matched study. Transplantation. 2011;91:348-353. doi: 10.1097/TP. 0b013e31820437da PMID: 21127462
16. Paramesh AS, Roayaie S, Doan Y, Schwartz ME, Emre S, Fishbein T, et al. Post-liver transplant acute renal failure: factors predicting development of end-stage renal disease. Clin Transplant. 2004;18:94-99. PMID: 15108777
17. Kim WH, Lee JH, Ko JS, Min JJ, Gwak MS, Kim GS, et al. Effect of remote ischemic postconditioning on patients undergoing living donorlivertransplantation. LiverTranspl. 2014;20:1383-1392. doi: 10. 1002/lt.23960 PMID: 25046844
18. Gassanov N, Nia AM, Caglayan E, Er F. Remote ischemic preconditioning and renoprotection: from myth to a novel therapeutic option? J AmSoc Nephrol. 2014;25:216-224. doi: 10.1681/ASN. 2013070708 PMID: 24309187
19. Burns KE, Chu MW, Novick RJ, Fox SA, Gallo K, Martin CM, et al. Perioperative N-acetylcysteine to prevent renal dysfunction in high-risk patients undergoing cabg surgery: a randomized controlled trial. Jama. 2005;294:342-350. PMID: 16030279
20. Bojan M, Gioanni S, Vouhe PR, Journois D, Pouard P. Early initiation of peritoneal dialysis in neonates and infants with acute kidney injury following cardiac surgery is associated with a significant decrease in mortality. Kidney Int. 2012;82:474-481. PMID: 22622499
21. Romano TG, Schmidtbauer I, Silva FM, Pompilio CE, D'Albuquerque LA, Macedo E. Role of MELD score and serum creatinine as prognostic tools for the development of acute kidney injury after liver transplantation. PLoSOne. 2013;8:e64089. doi: 10.1371/journal.pone.0064089 PMID: 23717537
22. Paugam-Burtz C, Kavafyan J, Merckx P, Dahmani S, Sommacale D, Ramsay M, et al. Postreperfusion syndrome during liver transplantation for cirrhosis: outcome and predictors. LiverTranspl. 2009;15:522-529. doi: 10.1002/lt.21730 PMID: 19399736
23. Varrier M, Ostermann M. Novel risk factors for acute kidney injury. CurrOpin Nephrol Hypertens. 2014;23:560-569. doi: 10.1097/MNH.0000000000000061 PMID: 25162200
24. Marvin MR, Morton V. Glycemic control and organ transplantation. J Diabetes SciTechnol. 2009;3:1365-1372. PMID: 20144390
25. Yoo YC, Shim JK, Song Y, Yang SY, Kwak YL. Anesthetics influence the incidence of acute kidney injury following valvular heart surgery. Kidney Int. 2014;86:414-422. doi: 10.1038/ki.2013.532 PMID: 24429400
26. Fukazawa K, Lee HT. Volatile anesthetics and AKI: risks, mechanisms, and a potential therapeutic window. J Am Soc Nephrol. 2014;25:884-892. doi: 10.1681/ASN.2013111215 PMID: 24511126
27. Selzner M, Kashfi A, Cattral MS, Selzner N, McGilvray ID, Greig PD, et al. Live donor liver transplantation in high MELD score recipients. Ann Surg. 2010;251:153-157. doi: 10.1097/SLA. 0b013e3181bc9c6aPMID: 19858705
28. Ryu HG, Jung CW, Lee HC, Cho YJ. Epinephrine and phenylephrine pretreatments for preventing postreperfusion syndrome during adult liver transplantation. Liver Transpl. 2012;18:1430-1439. doi: 10. 1002/lt.23511 PMID: 22821620
29. Guitard J, Cointault O, Kamar N, Muscari F, Lavayssiere L, Suc B, et al. Acute renal failure following liver transplantation with induction therapy. Clin Nephrol. 2006;65:103-112. PMID: 16509459
30. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41. PMID: 1244564
31. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med. 1999;130:461-470. PMID: 10075613
32. Concato J, Feinstein AR, Holford TR. The risk of determining risk with multivariable models. Ann Intern Med. 1993;118:201-210. PMID: 8417638
33. Siegert S, Yu Z, Wang-Sattler R, Illig T, Adamski J, Hampe J, et al. Diagnosing fatty liver disease: a comparative evaluation of metabolic markers, phenotypes, genotypes and established biomarkers. PLoSOne. 2013;8:e76813. doi: 10.1371/journal.pone.0076813 PMID: 24130792
34. Le Dell E, Petersen ML, Vander Laan MJ. Computationally efficient confidence intervals for cross-validated area under the ROC curve estimates. 2012.
35. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29-36. PMID: 7063747
36. De Long ER, De Long DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics. 1988;44:837-845. PMID: 3203132
37. Lindholm A. Cyclosporine A: clinical experience and therapeutic drug monitoring. Ther Drug Monit. 1995;17:631-637. PMID: 8588233
38. Jusko WJ, Thomson AW, Fung J, McMaster P, Wong SH, Zylber-Katz E, et al. Consensus document: therapeutic monitoring of tacrolimus (FK-506). Ther Drug Monit. 1995;17:606-614. PMID: 8588229
39. Gonwa TA, Mai ML, Melton LB, Hays SR, Goldstein RM, Levy MF, et al. End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment. Transplantation. 2001;72:1934-1939. PMID: 11773892
40. Cantarovich M, Tzimas GN, Barkun J, Deschenes M, Alpert E, Tchervenkov J. Efficacy of mycophenolate mofetil combined with very low-dose cyclosporine microemulsion in long-term liver-transplant patients with renal dysfunction. Transplantation. 2003;76:98-102. PMID: 12865793
41. Koch RO, Graziadei IW, Schulz F, Nachbaur K, Konigsrainer A, Margreiter R, et al. Long-term efficacy and safety of mycophenolate mofetil in liver transplant recipients with calcineurin inhibitor-induced renal dysfunction. Transpl Int. 2004;17:518-524. PMID: 15365603
42. Pfitzmann R, Klupp J, Langrehr JM, Neuhaus R, Junge G, Settmacher U, et al. Mycophenolate mofetil reduces calcineurin inhibitor-induced side effects after liver transplantation. Transplant Proc. 2002;34:2936-2937. PMID: 12431664
43. Hilmi I, Horton CN, Planinsic RM, Sakai T, Nicolau-Raducu R, Damian D, et al. The impact of postreperfusion syndrome on short-term patient and liver allograft outcome in patients undergoing orthotopic liver transplantation. Liver Transpl. 2008;14:504-508. doi: 10.1002/lt.21381 PMID: 18383079
44. Fukazawa K, Yamada Y, Gologorsky E, Arheart KL, Pretto EA Jr. Hemodynamic recovery following postreperfusion syndrome in liver transplantation. J Cardiothorac VascAnesth. 2014;28:1006-1014. doi: 10.1053/j.jvca.2014.02.017 PMID: 25107717
45. Ramsay M. The reperfusion syndrome: have we made any progress? Liver Transpl. 2008;14:412-414. doi: 10.1002/lt.21418 PMID: 18383086
46. Ryu HG, Jung CW, Lee CS, Lee J. Nafamostat mesilate attenuates Postreperfusion Syndrome during liver transplantation. Am J Transplant. 2011;11:977-983. doi: 10.1111/j.1600-6143.2011.03514.x PMID: 21521468
47. Cabezuelo JB, Ramirez P, Rios A, Acosta F, Torres D, Sansano T, et al. Risk factors of acute renal failure after livertransplantation. Kidney Int. 2006;69:1073-1080. PMID: 16528257
48. Dixon R, Brunskill NJ. Activation of mitogenic pathways by albumin in kidney proximal tubule epithelial cells: implications for the pathophysiology of proteinuric states. J AmSoc Nephrol. 1999;10:1487-1497. PMID: 10405204
49. Iglesias J, Abernethy VE, Wang Z, Lieberthal W, Koh JS, Levine JS. Albumin is a major serum survival factor for renal tubular cells and macrophages through scavenging of ROS. Am J Physiol. 1999;277:F711-722. PMID: 10564234
50. Kaufmann MA, Castelli I, Pargger H, Drop LJ. Nitric oxide dose-response study in the isolated perfused rat kidney after inhibition of endothelium-derived relaxing factor synthesis: the role of serum albumin. J Pharmacol ExpTher. 1995;273:855-862. PMID: 7752090
51. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesenti A, Romero M, et al. Albumin replacement in patients with severe sepsis or septic shock. N EnglJ Med. 2014;370:1412-1421. doi: 10.1056/NEJMoa1305727 PMID: 24635772
52. Van Den Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx F, Schetz M, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001;345:1359-1367. PMID: 11794168
53. Lecomte P, Van Vlem B, Coddens J, Cammu G, Nollet G, Nobels F, et al. Tight perioperative glucose control is associated with a reduction in renal impairment and renal failure in non-diabetic cardiac surgical patients. Crit Care. 2008;12:R154. doi: 10.1186/cc7145 PMID: 19055829
54. Ouattara A, Lecomte P, Le Manach Y, Landi M, Jacqueminet S, Platonov I, et al. Poor intraoperative blood glucose control is associated with a worsened hospital outcome after cardiac surgery in diabetic patients. Anesthesiology. 2005;103:687-694. PMID: 16192760
55. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283-1297. doi: 10.1056/NEJMoa0810625 PMID: 19318384
56. Griesdale DE, De Souza RJ, Van Dam RM, Heyland DK, Cook DJ, Malhotra A, et al. Intensive insulin therapy and mortality among critically ill patients: a meta-analysis including NICE-SUGAR study data. CMAJ. 2009;180:821-827. doi: 10.1503/cmaj.090206 PMID: 19318387
57. Park C, Hsu C, Neelakanta G, Nourmand H, Braunfeld M, Wray C, et al. Severe intraoperative hyperglycemia is independently associated with surgical site infection after livertransplantation. Transplantation. 2009;87:1031-1036. doi: 10.1097/TP.0b013e31819cc3e6 PMID: 19352123
58. Ammori JB, Sigakis M, Englesbe MJ, O'Reilly M, Pelletier SJ. Effect of intraoperative hyperglycemia during livertransplantation. J Surg Res. 2007;140:227-233. PMID: 17509267
59. Hilmi IA, Damian D, Al-Khafaji A, Planinsic R, Boucek C, Sakai T, et al. Acute kidney injury following orthotopic livertransplantation: incidence, riskfactors, and effects on patient and graft outcomes. BrJ Anaesth. 2015;114:919-926. doi: 10.1093/bja/aeu556 PMID: 25673576
60. Cittanova ML, Leblanc I, Legendre C, Mouquet C, Riou B, Coriat P. Effect of hydroxyethylstarch in brain-dead kidney donors on renal function in kidney-transplant recipients. Lancet. 1996;348:1620-1622. PMID: 8961992
61. Schortgen F, Lacherade JC, Bruneel F, Cattaneo I, Hemery F, Lemaire F, et al. Effects of hydroxyethylstarch and gelatin on renal function in severe sepsis: a multicentre randomised study. Lancet. 2001;357:911-916. PMID: 11289347
62. Dahm F, Georgiev P, Clavien PA. Small-for-size syndrome after partial livertransplantation: definition, mechanisms of disease and clinical implications. Am J Transplant. 2005;5:2605-2610. PMID: 16212618